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Abstract: In December 2019, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), began infecting humans, causing a novel disease, coronavirus disease 19 (COVID-19).
This was first described in the Wuhan province of the People’s Republic of China. SARS-CoV-
2 has spread throughout the world, causing a global pandemic. To date, thousands of cases of
COVID-19 have been reported in the United Kingdom, and over 45,000 patients have died. Some
progress has been achieved in managing this disease, but the biological determinants of health,
in addition to age, that affect SARS-CoV-2 infectivity and mortality are under scrutiny. Recent
studies show that several medical conditions, including diabetes and hypertension, increase the
risk of COVID-19 and death. The increased vulnerability of elderly individuals and those with
comorbidities, together with the prevalence of neurodegenerative diseases with advanced age, led us
to investigate the links between neurodegeneration and COVID-19. We analysed the primary health
records of 13,338 UK individuals tested for COVID-19 between March and July 2020. We show
that a pre-existing diagnosis of Alzheimer’s disease predicts the highest risk of COVID-19 and
mortality among elderly individuals. In contrast, Parkinson’s disease patients were found to have a
higher risk of SARS-CoV-2 infection but not mortality from COVID-19. We conclude that there are
disease-specific differences in COVID-19 susceptibility among patients affected by neurodegenerative
disorders.
Keywords: COVID-19; Parkinson’s disease; Alzheimer’s disease; SARS-CoV-2
1. Introduction
The rapid emergence of coronavirus disease 19 (COVID-19) has caused over one
million deaths worldwide [1]. The clinical features of patients affected by COVID-19 have
been extensively explored, but the predisposing factors contributing to increased trans-
mission and clinical severity remain unclear. Social and ecological health determinants
such as air pollution [2–5] have been suggested to increase the risk of infection and exac-
erbate COVID-19-related illness. In addition, several comorbidities have been proposed
to increase COVID-19 mortality rates, including cardiovascular and respiratory patholo-
gies [6,7]. The predominance of these comorbidities in advanced age, combined with the
increased incidence of mortality in elderly patients, suggests that age is a major risk factor
for COVID-19 mortality [8]. Given the increased incidence of neurodegenerative diseases
with ageing, these observations have raised concerns about the vulnerability of patients liv-
ing with chronic neurological conditions. Neurodegenerative diseases are a heterogeneous
group of diseases that are characterised by the progressive loss of neurons of the central
and peripheral nervous systems. Alzheimer’s disease (AD) is the most common neurode-
generative disorder and form of dementia worldwide and is characterised by neuronal
loss in the hippocampus and cortical areas leading to cognitive decline, memory loss [9,10].
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and it is
characterised by neuronal loss in the substantia nigra [11]. In contrast to AD, only a subset
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of PD patients develop dementia [11]. However, in both diseases, patients experience a
gradual worsening of their clinical condition as neuronal loss progresses, ultimately affect-
ing their quality of life. Importantly, patients affected by neurodegenerative disorders often
present with multiple age-related comorbidities [12]. These observations have led several
studies to investigate the hypothesis that individuals with neurodegenerative diseases
exhibit heightened susceptibility to COVID-19.
In one of the largest cohort studies of COVID-19 in Europe, data gathered from
166 hospitals in England, Scotland, and Wales showed that dementia was among the most
common comorbidities in the 20,133 patients hospitalised for COVID-19 after adjusting for
age and other confounders [13]. Similarly, a single-centre, retrospective, observational study
of 627 patients with COVID-19 in northern Italy showed that dementia and its progressive
stages were associated with increased mortality [14], consistent with previous findings [15].
While efforts are still ongoing to determine the exact biological basis underlying this
association, a recent community-based study revealed that the APOE ε4 genotype, a genetic
risk factor for both dementia and AD, is associated with an increased risk of severe COVID-
19 [9,10,16]. Taken together, these findings suggest that a dementia diagnosis may represent
an important risk factor for mortality in COVID-19 patients. However, it remains unclear
whether COVID-19 susceptibility varies across distinct subtypes of dementia, namely,
frontotemporal dementia, vascular dementia and AD. In addition, reports on the association
between other neurodegenerative disorders and COVID-19 are sparse, hindering both the
interpretation and the implementation of related findings into clinical practice. For instance,
it remains unclear whether individuals with parkinsonism, and in particular PD, are at
increased risk of COVID-19 death compared to the general population. Parkinsonism is
an umbrella term that encompasses a number of different neurological disorders grouped
together on the basis of several motor symptoms. The majority of patients affected by
parkinsonism have a positive diagnosis for PD [17].
As PD-related pathology often leads to respiratory muscle rigidity and an impairment
of the cough reflex at advanced stages of the disease [18], individuals suffering from this
condition may be at increased risk of COVID-19 mortality [19]. Although data are thus
far limited, it is conceivable that PD patients may be at elevated risk of severe respiratory
complications following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection or even unfavourable outcomes. In addition, it has been suggested that other
indirect factors of the pandemic, including increased stress, self-isolation, and anxiety,
as well as prolonged immobility, may further exacerbate the outcome of PD patients
affected by COVID-19 [20,21]. Currently, there is insufficient evidence to show that a
pre-existing diagnosis of PD increases the risk of COVID-19 or mortality, and contradictory
results have been reported from small samples of COVID-19 patients. A single-centre,
case-controlled telephone survey indicated that morbidity and mortality in patients with
mild to moderate PD did not differ from those in the general population [22]. Conversely,
a later phone survey showed that the COVID-19 prevalence among PD patients in Italy
is higher than the national average [23]. These studies provide useful insights into the
vulnerability of PD patients, but several methodological inconsistencies hamper their
interpretation. For instance, most studies to date include data from only hospitalised
or clinically suspected COVID-19 patients. Because a large proportion of SARS-CoV-2
infections are asymptomatic [24], these inclusion criteria likely underscore some degree of
misclassification, as hospital admission rates for COVID-19 depend on the prevalence of
community testing and admission criteria, which vary between countries.
Using comprehensive clinical data from the UK Biobank, we hypothesised that a
pre-existing diagnosis of dementia, AD or PD may be associated with increased risk of
COVID-19 and related death. To assess this hypothesis, we analysed baseline (2006–2010)
demographic characteristics and pre-existing diagnoses of 13,338 COVID-19 tested volun-
teers in the UK Biobank. This dataset contains the primary health records of participants
who were tested for COVID-19 since the beginning of this pandemic. We report that a pre-
existing diagnosis of dementia or AD predicts the largest risk of COVID-19 and mortality.
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Conversely, PD diagnosis was associated with an increased risk of SARS-CoV-2 infection
but not mortality from COVID-19.
2. Methods
2.1. UK Biobank Data Sources
The UK Biobank comprises health data from over 500,000 community volunteers
based in England, Scotland and Wales. Information about the geographical regions, recruit-
ment, and other characteristics has been previously described [25]. Briefly, between 2006
and 2010, adults aged between 40 and 69 years within close proximity to 1 of the 22 UK
Biobank recruitment centres were invited to participate. Individuals had extensive demo-
graphic, lifestyle, clinical and radiological information collected. Baseline assessments
also included a comprehensive series of questionnaires, face-to-face interviews, physical
examinations and blood sampling, with linkages to electronic medical records. Clinical
data on neurodegenerative disorders and other comorbidities were cross validated by an
algorithm from the UK Biobank, which took into consideration the UK Biobank baseline
assessment data (verbal interview), linked hospital admissions data, and death register
data [26]. Specifically, the diagnoses of neurodegenerative diseases and dementia relied
on consensus between primary care and hospital admissions and/or mortality data [27].
This method has been previously validated using a subset of the UK Biobank participants
and was shown to have high accuracies of detecting true positives [28]. The linkage method
of COVID-19 results to UK Biobank participants has been previously published [25,29].
The full protocol is publicly available, and summary data can be viewed on the UK Biobank
website: www.ukbiobank.ac.uk. UK Biobank ethical approval was granted from the North
West Multi-Centre Research Ethics Committee. The current analysis was approved under
the UK Biobank application #60124. A detailed list of the variables in the present study is
presented in Supplementary Table S1. We defined hypertension using the criteria of a dias-
tolic blood pressure ≥90 mmHg or systolic blood pressure ≥140 mmHg. Individual-level
data were collected from the UK Biobank on 17 August 2020.
2.2. Study Design and Exclusion Criteria
We conducted a cohort study using national primary care electronic health record
data linked to in-hospital COVID-19 death data (see UK Biobank data sources). Of the
13,338 participants with available COVID-19 data, 1626 tested positive for COVID-19
between 16 March and 26 July 2020, and 11,712 were negative. The majority of samples
tested for COVID-19 were derived from combined nose/throat swabs and analysed by
real-time polymerase chain reaction (RT-PCR). In intensive care settings, positive cases were
identified by a positive test result for SARS-CoV-2 in a hospital setting (i.e., participants
whose tests were taken while an inpatient or while attending an emergency department) or
death with a primary or contributory cause reported as COVID-19. More information on the
testing procedure can be found on the UK Biobank website [30]. During the same period,
COVID-19 testing in England was restricted to hospitalised patients with clinical signs
of the disease and healthcare workers. In contrast, all UK Biobank participants included
in this study were subjected to COVID-19 testing since the beginning of the pandemic.
For our models, we defined a positive outcome as either a positive COVID-19 diagnosis or
an in-hospital death in COVID-19-positive cases. Risk factors and covariates used for the
present analysis were selected on the basis of clinical interest and prior findings. These risk
factors and covariates are shown in Supplementary Table S1 and included dementia, AD,
PD, frontotemporal, vascular dementia, cancer, diabetes, high blood pressure, blood group,
age, sex, obesity, respiratory difficulties (chronic obstructive pulmonary disease (COPD)
and wheezing), forced expiratory volume (FEV), grey and white matter volume, brain
volume, white matter hyperintensity and C-reactive protein (CRP) levels. Obesity was
defined based on waist-to-hip ratio measurements. The waist-to-hip ratio is determined by
dividing waist circumference by hip circumference, meaning that overweight individuals
have higher ratios [31]. We grouped smoking status into current, former and never smokers.
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CRP total levels were normalised according to total protein levels and log-transformed to fit
a normal distribution. Other covariates considered as potential upstream risk factors were
population density, social deprivation, average household income, education level, housing
type, ethnicity, environmental risk within the workplace (chemical, diesel, dusty, smoke),
travel to work and the number of people per household. Deprivation was measured
using the Townsend Social Deprivation Index (TSDI [32], with higher values indicating
higher deprivation), which was derived from the patient’s postcode for a higher degree
of precision. Ethnicity was grouped into white or minority ethnicities. The full list of
minority groups used for our analysis can be found in Supplementary Table S2. For the
analysis of the association between PD and COVID-19, we included both incident (those
individuals in whom the diagnosis was recorded after their UK Biobank initial assessment
visit) and prevalent cases of PD (individuals diagnosed with PD prior to their initial
assessment visit). Under all circumstances, PD diagnoses were derived from self-report
or linked Hospital Episode Statistics International Classification of Diseases (ICD) codes,
as described elsewhere [33].
Our cohort included 157 participants with parkinsonism, of whom 142 were diagnosed
with PD. To account for potential differences between parkinsonism and PD in the context
of COVID-19-related vulnerability [19], we built 2 separate models—one with individuals
diagnosed with parkinsonism and one with PD patients only. Information on all covariates
was obtained from primary care records provided by the UK Biobank. The geographical
distribution of each subject included in the analysis is shown in Figure 1.
2.3. Statistical Analysis
For our analyses of COVID-19 and mortality, we fitted binomial regressions where
the response variables were COVID-19 positivity or COVID-19-related death (Figure 1A).
We defined COVID-19-related death as an individual who tested positive for COVID-19
and died.
We first took an exploratory approach and included several putative comorbidities
presented in the “Study section and exclusion criteria”. More specifically, we omitted
several variables, including FEV, COPD, and environmental risk within the workplace,
any brain-imaging-derived variable, and travel to work, due to a large number of indi-
viduals having missing data. We then applied an iterative variable selection procedure
combining unsupervised stepwise forward and stepwise backward regression analyses to
select the most suitable predictor or combination of predictors in our models based on the
Akaike information criterion. We calculated the odds or risk ratios and their 95% confidence
intervals to quantify the effects of the independent variables on the response variables.
These exploratory models showed an association between pre-existing dementia
diagnosis and COVID-19 and mortality. We therefore further pursued the link between
neurodegenerative diseases and COVID-19 outcome using the same analysis workflow.
To further confirm whether diagnoses of AD or PD were associated with COVID-19
death, we created a subset of the data to include only participants with the selected neu-
rodegenerative disease. We calculated the odds of dying from COVID-19 while accounting
for the comorbidities identified in the previous model, which assessed the association
between COVID-19 mortality and neurodegenerative diseases.
All models were built using the MASS package [34] in R. The comparison tables were
generated using the Stargazer package [35]. The analysis source code, detailed quality
checks and all supplementary material are available in GitHub (https://m1gus.github.io/
AD_PD_COVID19/). Statistical significance was defined as p ≤ 0.05.
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3. Results
3.1. AD a d PD Diagnoses Are Associated with an Increase in SARS-CoV-2 Infections in the UK
Biobank Cohort
To explore the links between neurodegenerative diseases and COVID-19, we first
estimat d the ris between COVID-19 and chronic diseases. Chronic diseases ften coexist
in older adul s [36–38]. Therefore, we assessed th ir risk aft r adjusting for other existing
comorb dities (see Figure 1A for the workflow) for an aged and predominant y white
cohort in Great Britain (Figure 1B,C). We found that a pre-existing diagnosis of ementia
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was associated with the largest increase in the likelihood of testing positive for COVID-19
(OR 3.25; 95% CI 2.73–3.87). This was followed by an increased waist-to-hip ratio (OR 3.07;
95% CI 2.26–4.17), a low education level (OR 1.67; 95% CI 1.38–2.02), a higher number
of people per household (OR 1.05; 95% CI 1.03–1.07) and an increased TSDI (OR 1.03;
95% CI 1.02–1.04) (Figure 2A and Supplementary Table S3). Our findings confirm previous
studies showing that dementia predicts one of the highest risks of COVID-19 in elderly
individuals [16,39]. Furthermore, consistent with previous observations [40], our primary
analysis identified white ethnicity (OR 0.72; 95% CI 0.66–0.77), cancer (OR 0.81; 95% CI
0.74–0.89) and decreasing age (OR 0.97; 95% CI 0.97–0.97) as significant predictors of SARS-
CoV-2 infectivity after adjusting for multiple confounding factors (Figure 2A). As recent
studies highlighted links between the global burden of dementia and COVID-19 death [39],
we next assessed whether the diagnosis of dementia increased the risk of COVID-19
mortality in the UK Biobank participants. Similar to the COVID-19 models, we found that
a diagnosis of dementia was associated with the largest risk of mortality from COVID-19
(OR 4.32; 95% CI 3.33–5.60), followed by male sex (OR 1.44; 95% CI 1.20–1.73), increased age
(OR 1.09; 95% CI 1.08–1.07), and an increased TSDI (OR 1.07; 95% CI 1.05–1.09) (Figure 2B
and Supplementary Table S4). Cancer was negatively associated with an increased risk of
mortality in our cohort (OR 0.56; 95% CI 0.44–0.72).
Given the prominent role of dementia in COVID-19 diagnoses, we next sought to
increase the granularity of our analysis by examining distinct subtypes of dementia. For the
analysis of our PD cohort, we observed that only a small subset of patients was diagnosed
with dementia (n = 10). Given the small sample size, we proceeded to exclude PD individ-
uals with clinically diagnosed dementia from our analysis and included only PD patients
without dementia (n = 142). Overall, the cumulative incidence of PD and AD diagnosis
among COVID-19-positive patients in our cohort was 1.7% and 1.6%, respectively. Our
results show that a diagnosis of AD was strongly associated with SARS-CoV-2 infectivity,
with AD patients showing the greatest susceptibility to SARS-CoV-2 infectivity compared
to individuals without AD (OR 4.15; 95% CI 3.22–5.34). We also found that an increase
in the waist-to-hip ratio (OR 3.08; 95% CI 2.27–4.19) or pre-existing vascular dementia
(OR 2.51; 95% CI 1.69–3.71) were also positively associated with COVID-19 (Figure 3A
and Supplementary Table S5). PD diagnosis also emerged as a strong positive predictor of
COVID-19 (OR 1.74; 95% CI 1.34–2.27), although the effect was smaller than that for AD
diagnosis. Low education level (OR 1.65; 95% CI 1.36–2.0), a higher number of people per
household (OR 1.05; 95% CI 1.03–1.07) or an increased TSDI (OR 1.03; 95% CI 1.02–1.04)
emerged as significant predictors of a positive COVID-19 diagnosis (Figure 3). Our analysis
shows that patients of white ethnicity (OR 0.72; 95% CI 0.66–0.77) or with a pre-existing
diagnosis of cancer (OR 0.81; 95% CI 0.72–0.88) were at lower risk of infection in our
cohort, while increasing age did not predict an increased risk of infection (OR 0.97; 95% CI
0.97–0.97; Figure 3A). We further investigated whether there was any difference in the risk
of testing positive for COVID-19 in participants with parkinsonism (n = 157) compared
to a subset of patients with PD (n = 142). We show that including all participants with
parkinsonism led to similar results (OR 1.71; 95% CI 1.37–2.14; Supplementary Table S6).
We conclude that diagnoses of AD, vascular dementia and PD increased the risk of testing
positive for COVID-19 in UK Biobank participants.
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cases (A) or deaths (B). For simplicity, characteristics were subgrouped into three categories, namely,
‘comorb dities’, ‘other risk factor and ‘socio-economic’. Red indicates significant associations
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3.2. AD Patients Are at Higher Risk of COVID-19 Death
Although our results show that patients with AD, PD and vascular dementia are
at increased risk of contracting COVID-19, it remains unclear whether the presence of
neurodegenerative disorders may exacerbate the risk of mortality in COVID-19 patients.
To address this issue, we examined the characteristics and outcomes of all COVID-19
patients in the cohort using a binary multivariable regression model (Figure 3B and
Supplementary Table S7). In terms of neurodegenerative diseases, a diagnosis of fron-
totemporal dementia (OR 16.36; 95% CI 5.44–49.15) was associated with the largest risk of
COVID-19 death, but this observation suffers from a small sample size (n = 6), so we did
not explore frontotemporal dementia further in our analysis. We observed that diagnoses
of AD (OR 4.17; 95% CI 2.87–6.05) were associated with COVID-19 death but not diagnoses
of PD or vascular dementia. In our model, a pre-existing diagnosis of cancer was negatively
associated with COVID-19 death (OR 0.63; 95% CI 0.51–0.79), and no significant associa-
tion was found with diabetes, C-reactive protein levels or ethnicity and COVID-19 death
(Figure 3B). We also found that a higher TSDI increased the risk of COVID-19 adverse
outcomes (OR 1.07; 95% CI 1.05–1.09), while an increased waist-to-hip ratio (OR 5.83;
95% CI 2.18–15.58) or male sex (OR 1.38; 95% CI 1.16–1.65) were positively associated with
COVID-19 death, but this relationship did not reach statistical significance.
We next focused on the role of AD in COVID-19-related deaths. We first built a model
that contained only participants with a positive AD diagnosis. Using this model, we found
that none of the previously mentioned comorbidities were significant. This observation
indicates that participants with AD were at higher risk of dying from COVID-19, inde-
pendent of age, sex and other comorbidities (Supplementary Table S8). We used a similar
workflow to further show that a diagnosis of PD was not a predictor of COVID-19-related
death. In our model containing only participants with a positive PD diagnosis, we show
that age, the TSDI and obesity were significant predictors of COVID-19-related death,
indicating that other comorbidities in participants with PD may explain their risk of dying
from COVID-19 (Supplementary Table S9).
4. Discussion
Despite considerable uncertainty in estimates of COVID-19 outcomes, age and co-
morbid medical conditions are consistently associated with adverse health outcomes in
hospitalised COVID-19 patients [15]. The incidence of neurological conditions, including
dementia and neurodegenerative diseases, increases with age, and it has recently been
proposed that individuals with a pre-existing diagnosis of dementia may be at increased
risk of developing COVID-19 [16]. In previous viral outbreaks of respiratory pathogens,
including severe acute respiratory syndrome, Middle East respiratory syndrome, and H1N1
influenza, several reports also highlighted the presence of neurological comorbidities in
affected patients [41,42]. In the present study, we found that the largest risk factor as-
sociated with COVID-19 was a pre-existing diagnosis of dementia associated with AD,
vascular dementia or PD. However, while the diagnosis of AD also predicted an increased
risk of COVID-19 mortality, our findings suggest that COVID-19 mortality among PD and
vascular dementia patients does not differ from that in the general population.
Thus far, several studies have suggested a relationship between COVID-19 and neu-
rodegenerative disorders. An early report [19] this year showed that a dementia diagnosis
was associated with the largest increase in the risk of COVID-19 in the UK Biobank based
on a smaller cohort of 507 COVID-19-positive patients from England aged 65 and older.
Dementia has also been found to increase the risk of in-hospital mortality in a large cross-
sectional analysis of 20,133 patients already hospitalised for COVID-19 in the UK [13],
a finding later replicated by two cohort, retrospective studies [14,15]. However, these
studies mostly focused on hospitalised individuals and did not include data on patients
managed in community settings, such as domestic residences. In addition, in line with
government guidelines, testing procedures were limited to individuals with COVID-19
symptoms, meaning that available data fail to include the growing number of people who
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are asymptomatic or are self-isolating at home due to mild symptoms [13]. Using granular
data from the UK Biobank, we developed a more robust analysis pipeline since all partici-
pants in our dataset received COVID-19 testing. Because a large proportion of SARS-CoV-2
infections are asymptomatic, this screening protocol is more sensitive for the analysis of
COVID-19 and mortality rates among people diagnosed with neurodegenerative diseases.
Our results indicate that AD patients are at increased risk of COVID-19. These findings
expand a recent analysis of 1091 COVID-19-positive individuals from the UK Biobank.
In this study, Zhou and colleagues employed a logistic regression analysis of pre-existing
conditions that are overrepresented in patients with COVID-19 and showed that AD was
the most significant risk factor for COVID-19, although its association with increased
COVID-19 mortality was not investigated [43]. Here, we build on these earlier observations
to show that AD is a major risk factor associated with COVID-19 mortality after accounting
for a large number of comorbidities. Several features of AD may increase the risk of
COVID-19 adverse outcomes. First, the neuropathology of AD could facilitate COVID-
19 complications. Increasing evidence from animal studies suggests that amyloid fibrils
induce microglial activation and increased activation of the type-1 interferon (IFN) pathway,
a crucial component of COVID-19 [44]. Current theories propose that the IFN response
in AD may synergise with COVID-19 upon SARS-CoV-2 infection, creating the ‘perfect
storm’ of excessive immune responses and thus exacerbating pathology [45]. Supporting
the hypothesis of a neurobiological link between AD and COVID-19 mortality, a recent
pathological examination of post-mortem tissue from AD patients demonstrated that the
protein expression levels of angiotensin-converting enzyme 2 (ACE2), the entry receptor
for SARS-CoV-2, were upregulated in the brains of AD patients [46]. This finding raises the
hypothesis that higher ACE2 expression may underscore higher viral load in the brains of
AD patents, corroborating a potential link between AD neuropathology and COVID-19
mortality [47]. Finally, the social behaviour of patients with dementia and AD must be
considered. Cognitive decline may compromise the ability of individuals with AD to follow
the recommendations of public health authorities, increasing the likelihood of contagion
and the need for carers [48]. Behavioural and psychological symptoms (BPSD) of dementia
and AD, such as motor agitation, intrusiveness, or wandering, may further undermine
efforts to maintain isolation.
We also found that PD is associated with a heightened risk of SARS-CoV-2 infectivity
but not mortality. This is consistent with two recent studies from Italy showing increased
COVID-19 mortality rates among PD patients. One group gathered clinical information
on 120 community-dwelling PD patients and reported a mortality rate of 20%, a value
significantly higher than that of the general population [49]. The second study found that
PD patients of older age (>78 years) displayed increased susceptibility to COVID-19 death
compared to younger patients [20]. However, both studies used clinically suspected (non-
laboratory confirmed) COVID-19 cases, which complicates their interpretation. As noted by
the authors, the increased susceptibility to COVID-19 may have resulted in some patients
being incorrectly identified as COVID-19-positive, thus leading to a misclassification of
COVID-19-related deaths. Moreover, the accuracy of prevalence data might further be
hampered by the existence of asymptomatic cases and the lack of population screening
campaigns in Italy. Our results support those of a recent case-controlled study that showed
that PD was not associated with any apparent risk of morbidity and mortality compared to
the general population [22].
Although the biological basis for the higher mortality rate in AD compared to PD
patients remains to be elucidated, a recent commentary suggested that PD neuropathology
itself might exercise a neuroprotective effect against COVID-19 [50]. For instance, SARS-
CoV-2 binds to the ACE2 receptor, which is highly expressed in dopaminergic neurons
of the striatum [51]. However, PD-related neuropathology induces significant degenera-
tion of these neurons, raising the hypothesis of reduced neuroinvasion in these patients,
as proposed elsewhere [50]. Second, increased neuronal expression of α-synuclein follow-
ing acute West Nile virus infection suggests that this protein could function as a native
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antiviral factor within neurons [52]. Finally, a number of PD drugs have been hypothesised
to play a therapeutic role in COVID-19. Among these, accumulating evidence shows
that amantadine may inhibit viral replication and protect against severe outcomes in PD
patients [53]. The proposed mechanism of action involves a disruption of the lysosomal
machinery needed for viral replication [54], and there is preliminary evidence of a pro-
tective effect against COVID-19 in a small cohort of PD patients, all taking L-DOPA and
having tested positive for COVID-19 [55]. In the present study, none of the PD patients
receiving amantadine treatment developed severe complications from COVID-19, and only
one patient tested positive for SARS-CoV-2 (Supplementary Tables S10 and S11). Although
limited by a small sample size, our preliminary analysis is in line with the hypothesis that
amantadine may exert a protective effect against both COVID-19 and mortality. Further
clinical studies should be conducted to corroborate the therapeutic utility of amantadine
for the treatment of COVID-19.
5. Limitations
This study presents several caveats. First, our cohort is not representative of the UK
population. For instance, the majority of COVID-19-related deaths in the UK took place
in care homes [56]. However, only six patients included in our study were reported to
live in long-term care facilities, and none of them tested positive for COVID-19. Therefore,
our analysis of patients affected by chronic neurodegenerative diseases included only pa-
tients living in domestic residences where rapid changes in social behaviour and domestic
care may have affected distinct patient groups differently. This feature might have led us
to overestimate the effect of chronic neurodegenerative disorders on the risk of COVID-19
and mortality, and further investigation is needed to confirm the generalisability of our
results. In addition, it is important to recognise the indirect effects of the current pandemic
on AD patients. Because elderly individuals are at increased risk of severe outcomes
from COVID-19, government guidelines recommend the isolation of these individuals
and limited contact with their family members [57]. However, social activities as well as
time spent with other people are generally considered to help prevent cognitive decline in
elderly individuals [58]. Therefore, it is plausible that isolation, albeit necessary, may lead
to increased stress and cognitive decline among AD patients [59]. In turn, these behavioural
difficulties may exacerbate underlying neurodegenerative disorders, contributing to higher
rates of hospitalisation and a higher risk of COVID-19 and mortality [59]. Our findings
warrant a more rigorous assessment of functional disabilities in patients with AD and
PD and their association with COVID-19 mortality. While these effects are challenging to
measure in the midst of a pandemic, large-scale retrospective studies will reveal the full
range of implications of current isolation measures on AD and COVID-19. Finally, several
potentially relevant comorbidities, such as kidney disease, previous myocardial infarction,
and stroke, were not included in data collection. Future studies should validate our re-
sults by examining the effect of additional comorbidities as well as other factors that we
were unable to examine, including access to personal protective equipment, employment,
exposure to environmental hazards and the effect of living in care home facilities.
6. Conclusions
In conclusion, we report that a pre-existing diagnosis of dementia or AD predicted the
largest risk of COVID-19 and mortality. Conversely, PD patients were found to be at height-
ened risk of SARS-CoV-2 infection but not mortality from COVID-19. Our results support
detailed analyses of the biological mechanisms underlying disease-specific vulnerability
to SARS-CoV-2 infection among patients with neurodegenerative disorders. Improved
knowledge of these factors is critical to develop appropriate strategies to protect clinically
vulnerable patients affected by neurodegenerative diseases during this pandemic.
Our results have important implications for disease management and further highlight
an important role of disease-specific neuropathology and management in the potential
susceptibility to COVID-19.
Geriatrics 2021, 6, 10 12 of 15
Supplementary Materials: The following are available online at https://www.mdpi.com/2308-341
7/6/1/10/s1, Table S1: Descriptive statistics of the UK Biobank cohort data. This table is related to
Figure 1. Baseline characteristics of 13,338 UK Biobank participants included in the study. The C-
reactive protein levels were normalised to total protein levels and log-transformed. White matter
hyperintensity levels were normalised to total brain volumes and log-transformed. The household
number refers to the number of people per household. N-Miss, number of missing values; SD,
standard deviation; A-levels/AS levels, participants with Advanced Level (A-level) or Advanced
Subsidiary Level (AS level) qualifications. NVQ/HND/HNC, participants who received vocational
qualifications such as National Vocational Qualifications (NVQ), Higher National Certificate (HNC)
or Higher National Diploma (HND); CSEs, participants with a Certificate of Secondary Education
(CSEs); O-levels/GCSEs, participants with either a General Certificate of Secondary Education (GCSE)
or a General Certificate of Education (GCE) Ordinary Level (O-levels), a secondary school leaving
qualification. Table S2: Descriptive statistics for minority groups in the UK Biobank. This table is
related to Figure 1. Summary of the number of individuals from each ethnic group included in the
analysis and the outcomes of the COVID-19 test. The data are presented as the number of patients,
followed by the percentage of the number of participants relative to the total number of participants
in parentheses. N-Miss, number of missing values. Table S3: The diagnosis of dementia increases the
risk of COVID-19. This table is related to Figure 2A. Risk factors associated with COVID-19 diagnosis
in the UK Biobank cohort. The household number refers to the number of people per household.
The odds ratios for education levels are relative to A-levels. NVQ/HND/HNC, participants who
received vocational qualifications such as National Vocational Qualifications (NVQ), Higher National
Certificate (HNC) or Higher National Diploma (HND); CSEs, participants with a Certificate of
Secondary Education (CSEs); O-levels/GCSEs, participants with either a General Certificate of
Secondary Education (GCSE) or a General Certificate of Education (GCE) Ordinary Level (O-levels),
a secondary school leaving qualification. Table S4: The diagnosis of dementia increases the risk
of COVID-19 death. This table is related to Figure 2B. Risk factors associated with both testing
positive and dying from COVID-19 within the UK Biobank cohort. Blood pressure is relative to
participants who were not tested for blood pressure. Smoking is relative to being a current smoker.
The C-reactive protein levels were normalised to total protein levels and log-transformed. The
household number refers to the number of people per household. Table S5: Diagnoses of Alzheimer’s
and Parkinson’s diseases increase the risk of COVID-19. This table is related to Figure 3A. Risk
factors associated with COVID-19 diagnosis in the UK Biobank cohort. The household number
refers to the number of people per household. The odds ratios for education levels are relative to
A-levels. NVQ/HND/HNC, participants who received vocational qualifications such as National
Vocational Qualifications (NVQ), Higher National Certificate (HNC) or Higher National Diploma
(HND); CSEs, participants with a Certificate of Secondary Education (CSEs); O-levels/GCSEs,
participants with either a General Certificate of Secondary Education (GCSE) or a General Certificate
of Education (GCE) Ordinary Level (O-levels), a secondary school leaving qualification. Table S6:
Diagnoses of Alzheimer’s disease and parkinsonism increase the risk of COVID-19. Risk factors
associated with COVID-19 diagnosis in the UK Biobank cohort. The household number refers to
the number of people per household. The odds ratios for education levels are relative to A-levels.
NVQ/HND/HNC, participants who received vocational qualifications such as National Vocational
Qualifications (NVQ), Higher National Certificate (HNC) or Higher National Diploma (HND); CSEs,
participants with a Certificate of Secondary Education (CSEs); O-levels/GCSEs, participants with
either a General Certificate of Secondary Education (GCSE) or a General Certificate of Education
(GCE) Ordinary Level (O-levels), a secondary school leaving qualification. Table S7: The diagnosis of
Alzheimer’s disease increases the risk of COVID-19 death. This table is related to Figure 3B. Risk
factors associated with both testing positive for and dying from COVID-19 within the UK Biobank
cohort. The C-reactive protein levels were normalised to total protein levels and log-transformed.
Table S8: Participants with Alzheimer’s disease have an increased risk of dying from COVID-19,
independent of other common risk factors. Risk factors associated with both testing positive for
and dying from COVID-19 within the UK Biobank cohort in the subset of patients with a positive
diagnosis of Alzheimer’s disease. The model shows that a diagnosis of Alzheimer’s disease increased
the risk of COVID-19 death, independent of underlying risk factors characterising the Alzheimer’s
disease patients within the UK Biobank. Table S9: The diagnosis of Parkinson’s disease does not
explain the risk of COVID-19 death. Risk factors associated with dying from COVID-19 within the
UK Biobank cohort in the subset of patients with a positive diagnosis of Parkinson’s disease. The
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model shows that a diagnosis of Parkinson’s disease did not explain the risk of COVID-19 death,
indicating that other comorbidities in participants with PD may explain their risk of dying from
COVID-19. Table S10: Effect of drug treatment on COVID-19 mortality in the UK Biobank. Effect of
drug treatments on COVID-19 mortality in the UK Biobank cohort. For each drug treatment (Drug
treatment), the number of patients (Number of participants) taking the drug (TRUE) and not taking
the drug (FALSE) were defined and compared to the number of patients who died from COVID-19
(COVID-19 death) compared to the total number of patients in the UK Biobank tested for COVID-19
(Total participants tested). The percentage of the number of participants relative to the total number
of participants is indicated in parentheses. Table S11: Demographic and clinical characteristics
of amantadine-treated patients. Demographic and clinical characteristics of amantadine-treated
participants (n = 9) included in the study. The household number refers to the number of people per
household. Housing type refers to the type of accommodation in which patients live (flat/maisonette,
house/bungalow, caravan, sheltered accommodation, care home). NVQ/HND/HNC, participants
who received vocational qualifications such as National Vocational Qualifications (NVQ), Higher
National Certificate (HNC) or Higher National Diploma (HND); CSEs, participants with a Certificate
of Secondary Education (CSEs); O-levels/GCSEs, participants with either a General Certificate of
Secondary Education (GCSE) or a General Certificate of Education (GCE) Ordinary Level (O-levels),
a secondary school leaving qualification.
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